To The Moon

UnitedHealth Group has released the voting results from its 2026 Annual Meeting of Shareholders and announced related board actions. The meeting, held recently, saw shareholders vote on several corporate governance matters.

According to the company's announcement, shareholders voted to approve the following items: all nine incumbent directors were re-elected, including Charles Baker, Timothy Flynn, Paul Garcia, Kristen Gil, Dr. Scott Gottlieb, Stephen Hemsley, F. William McNabb III, Dr. Valerie Montgomery Rice, and Dr. John Noseworthy. Additionally, shareholders approved, on an advisory basis, the company's executive compensation plan and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year. However, a shareholder proposal requiring the Chair of the Board to be an independent director was not approved.

In its regular quarterly meeting following the annual session, the Board of Directors declared a quarterly cash dividend of $2.32 per share. This dividend is payable on June 23, 2026, to shareholders of record as of the close of business on June 15, 2026. This distribution continues UnitedHealth Group's long-standing policy of returning value to shareholders; the company has now paid dividends for 34 consecutive years and increased its dividend for 16 consecutive years.

Beyond the resolutions mentioned, the board also discussed committee appointments. The board had previously established a new Public Accountability Committee to enhance the company's focus on its mission, stakeholder trust, and public accountability. The successful conclusion of the annual meeting and the passage of these resolutions lay a foundation for the company's governance structure and strategic execution for the coming year.

As a global leader in healthcare, UnitedHealth operates through its UnitedHealthcare and Optum businesses, providing health benefits and services to approximately 51 million people. The company will continue to optimize its capital allocation through dividends and share repurchases while advancing investments in artificial intelligence and digital transformation to enhance operational efficiency and reduce healthcare costs.